Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-PSMA-T4
- Development stage
- Unknown
- Lead developer
- National Centre for Nuclear Research
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
99mTc-PSMA-T4 is a diagnostic radiopharmaceutical developed by the National Centre for Nuclear Research (Narodowe Centrum Badań Jądrowych - POLATOM) in Poland for the imaging of prostate cancer. It consists of a small-molecule peptide ligand, T4, which exhibits high affinity for the prostate-specific membrane antigen (PSMA), a protein significantly overexpressed on the surface of prostate cancer cells. The ligand is chelated to technetium-99m (99mTc), a gamma-emitting radioisotope widely used in nuclear medicine. Upon intravenous administration, the tracer binds to PSMA-positive tumor sites, allowing for their visualization and localization using Single Photon Emission Computed Tomography (SPECT) combined with Computed Tomography (CT). The agent is primarily intended for the staging of high-risk prostate cancer and the detection of recurrence in patients with biochemical failure.
- Other names
- [99mTc]Tc-PSMA-T4technetium Tc 99m PSMA-T4technetium (99mTc) PSMA-T4
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 99mTc-PSMA-T4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-PSMA-T4.